Evidence-based asthma management

Area of Science:

• Pediatric Pulmonology
• Allergy and Immunology
• Pharmacology

Background:

• National Asthma Education and Prevention Program guidelines exist but leave management issues unresolved.
• Inhaled corticosteroids (ICS) are a cornerstone of pediatric asthma management.
• Alternative therapies and delivery methods require further investigation.

Purpose of the Study:

• To review current evidence on pediatric asthma management strategies.
• To compare the efficacy and safety of various asthma medications.
• To identify areas needing further research in asthma care.

Main Methods:

• Systematic review of evidence-based guidelines and clinical studies.
• Comparative analysis of inhaled corticosteroids, beta(2) agonists, leukotriene modifiers, and other agents.
• Evaluation of safety data, including ocular and HPA axis effects.

Main Results:

• Inhaled corticosteroids are more effective than as-needed beta(2) agonists and long-acting beta(2) agonists for children.
• Leukotriene modifiers are a viable oral alternative but not preferred over inhaled options.
• Cromolyn sodium and nedocromil are less effective than ICS; evidence for cromolyn in childhood asthma maintenance is insufficient.
• No significant ocular toxicity or HPA axis effects observed with low-to-medium dose ICS in children.
• Antibiotics are not indicated unless bacterial comorbidity exists; heliox may benefit early acute attacks.

Conclusions:

• Inhaled corticosteroids offer superior asthma control in children with a favorable risk-benefit profile.
• Further research is needed on asthma action plan effectiveness (symptoms vs. peak flow) and the sinusitis-asthma exacerbation link.
• Metered-dose inhalers and other aerosol devices have comparable efficacy; cost-effectiveness should guide selection.